



CFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 5151**  
Albert C. GYORKOS et al. : Attorney Docket No. 2007\_0505  
Serial No. 10/577,334 : Group Art Unit 4121  
Filed April 28, 2006 : Examiner Alicia L. Fierro  
NITROGEN-CONTAINING FUSED  
HETEROCYCLIC COMPOUNDS : **Mail Stop: AMENDMENT**

---


**RESPONSE TO RESTRICTION/SPECIES ELECTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Restriction/Species Election Requirement dated December 31, 2008, Applicants hereby elect the invention identified as Group I, claims 1-12 and 17-18, drawn to a compound of formula (I), an agent and a prodrug comprised of said compound.

Applicants further elect N<sup>2</sup>-(4-chloro-2-methoxy-6-methylphenyl)-N<sup>7</sup>,N<sup>7</sup>-diethyl-1-methyl-1*H*-benzimidazole-2,7-diamine as the species of the compound. This compound can be found in Example 170, page 227, of the specification as filed. The structure of the claimed compound is shown below:



As required by the Office, the substituents of formula (I) are identified as follows:

Ring A = A'

X = C

X<sup>1</sup> = NR<sup>5</sup>

R<sup>5</sup> = Hydrocarbyl

R<sup>1</sup> = (1) an amino substitute by two substituents selected from an optionally substituted Hydrocarbyl group

R<sup>2</sup> = optionally substituted Aryl

Z = NR<sup>4</sup>

R<sup>4</sup> = H

Y<sub>1</sub>, Y<sub>2</sub>, Y<sub>3</sub> = Methyne

W = bond


Applicants further elect depression as the species of the disease.

It is respectfully submitted that at least claims 1-3, 6, 8-12 and 17-18 are readable on the elected species.

Favorable action on the merits is now requested.

Respectfully submitted,

Albert C. GYORKOS et al.

By: 

William R. Schmidt, II  
Registration No. 58,327  
Attorney for Applicants

WRS/lc  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
January 23, 2009